Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: scott harrison who wrote (320)	12/4/1997 3:04:00 PM
From: Tom D	Read Replies (1) \| Respond to of 887

You could do it that way. I think that part of why NSTA dropped 4 points on the first day of trading after approval was because 1) the price had run up too far, and 2) people like myself expected them to have trouble getting Actiq reimbursed by third party payers. Greedy HMO's my not want to pay exorbitant prices for optimizing pain control. I sold 12,000 shares of NSTA short at the resumption of trading. I don't forsee reimbursement problems with DepoCyt. I expect full FDA approval in early 1998. Nonetheless you might be smart to sell some or all of your position, either upon ODAC's favorable recommendation or upon full approval. In general, the anouncement of good news is a good time to consider selling all or part of one's position. You might want to consider placing a sell order at the market for some portion of your holdings before trading resumes on the 19th. But when you start trading these stocks, you are competing with other traders who usually have more information and faster computers than you. My own decision will depend on where the price is, what Marty Zweig thinks about the overall market, what kind of small cap rally is going on, and what my level 2 quotes are telling me about where things are going. I will probably try to sell at least half of my 65,000 shares in DEPO around that time because I am significantly margined, my portfolio is in no way balanced, and I want to buy some other things too. But I like DEPO as a long-term investmet. I believe it will get full FDA approval in early 1998 and biotechs tend to do well in late December and January. So, I don't think this is a black and white, all or none, obvious decision. Incidentally, I was pleased to see GLIA finally get going today. You know they have an advisory committee meeting a week fom today. Their stock has been sitting around 11 or 12 ever since they announced their meeting. Today it finally broke out, up to 13 1/2 on heavy volume, heralding the arrival of the traders! I did buy 5000 shares of GLIA at 13 1/8 this afternoon, just for a week of trading. But I think DEPO is a better investment than GLIA in all time frames, so I didn't really do much with GLIA. Anyway, I figure it will be a week more, at the longest, before DEPO says goodby to the 15's and 16's. Best Regards, Tom